← Back to Clinical Trials
Recruiting NCT05545865

NCT05545865 Chardonnay Marc and Vascular Response

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05545865
Status Recruiting
Phase
Sponsor University of California, Davis
Condition Cardiovascular Diseases
Study Type INTERVENTIONAL
Enrollment 5 participants
Start Date 2022-09-01
Primary Completion 2026-08-24

Eligibility & Interventions

Sex Male only
Min Age 30 Years
Max Age 50 Years
Study Type INTERVENTIONAL
Interventions
Low Flavanol Cocoa PowderHigh Flavanol Cocoa PowderVine to Bar Chocolate - 2 servings

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 5 participants in total. It began in 2022-09-01 with a primary completion date of 2026-08-24.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to obtain data on the potential influence of Vine to Bar product(s) containing Chardonnay marc on cardiometabolic health. These initial studies will inform the design and timing of data collection for future dietary intervention trials that will examine the influence of Chardonnay marc intake on outcomes/biomarkers of both cardiometabolic health and the gut microbiome. This includes collecting data on the potential differences in response to the products based on the unique food matrix for each of the products that will be tested. Moreover, as there is a paucity of data on the influence of cocoa flavanol intake on vascular function beyond 4 hours post intake, the response of the selected outcomes will be assessed after 6 hours of flavanol intake. This is a time point that captures the increased circulating presence of microbial derived flavanol metabolites.

Eligibility Criteria

Inclusion Criteria: * Screening or Visit 1 Reactive Hyperemia Index (RHI; EndoPAT 2000) \< 2.0 * Subject is willing and able to comply with the study protocols. * Subject is willing to participate in all study procedures * BMI 25.0 - 35 kg/m2 Exclusion Criteria: * BMI ≥ 35 kg/m2 * Indivduals that weight less than a 110 lbs * Donation of blood within the previous 30 days * Visit 1 Reactive Hyperemia Index (RHI; EndoPAT 2000) ≥ 2.0 * 1 ug/ml and 3 ug/ml collagen screening maximal platelet aggregatory response of \< 65%. * Platelet counts \< 150,000 / ul * Anemia, which includes self report, or a screening hemoglobin and hematocrit that is less than the normal reference range or as diagnosed by study physician upon review of complete blood cell count reports. * Dislike or allergy for nuts, cocoa or grape products * Self-reported use of daily anticoagulation agents including aspirin, NSAIDs * Vegan, Vegetarians, food faddists or those consuming a non-traditional diet * Fruit consumption ≥ 3 cups/day * Vegetable consumption ≥ 4 cups/day * Nut intake ≥ 2 servings/ week * Coffee/tea ≥ 3 cups/day * Dark chocolate ≥ 3 oz/day * Self-reported restriction of physical activity due to a chronic health condition * Self-reported chronic/routine high intensity exercise * Self-reported diabetes * Blood pressure ≥ 140/90 mm Hg * Self-reported renal or liver disease * Self-reported heart disease, which includes cardiovascular events and stroke * Peripheral artery disease, Raynaud's syndrome * Inability to properly place or wear the PAT probes or abnormal measurements on pre- screening PAT * Self-reported cancer within past 5 years * Self-reported malabsorption * Currently taking prescription drugs or supplements. * Supplement use or unwillingness to stop any supplement use, including herbal, plant or botanical, fish oil, oil supplements a month prior to study enrollment. * Indications of substance or alcohol abuse within the last 3 years * smoking, vaping, cannabis use * Current enrollee in a clinical research study.

Contact & Investigator

Central Contact

Roberta R Holt

✉ rrholt@ucdavis.edu

📞 5304005952

Principal Investigator

Carl L Keen

PRINCIPAL INVESTIGATOR

Distinguished Professor Emeritus of Nutrition

Frequently Asked Questions

Who can join the NCT05545865 clinical trial?

This trial is open to male participants only, aged 30 Years or older, up to 50 Years, studying Cardiovascular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05545865 currently recruiting?

Yes, NCT05545865 is actively recruiting participants. Contact the research team at rrholt@ucdavis.edu for enrollment information.

Where is the NCT05545865 trial being conducted?

This trial is being conducted at Davis, United States.

Who is sponsoring the NCT05545865 clinical trial?

NCT05545865 is sponsored by University of California, Davis. The principal investigator is Carl L Keen at Distinguished Professor Emeritus of Nutrition. The trial plans to enroll 5 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology